169 related articles for article (PubMed ID: 37356337)
1. Tubulin degradation: Principles, agents, and applications.
Zhang YF; Huang J; Zhang WX; Liu YH; Wang X; Song J; Jin CY; Zhang SY
Bioorg Chem; 2023 Oct; 139():106684. PubMed ID: 37356337
[TBL] [Abstract][Full Text] [Related]
2. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
3. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
4. Conformation and energy investigation of microtubule longitudinal dynamic instability induced by natural products.
Chu Y; Tian Z; Yang M; Li W
Chem Biol Drug Des; 2023 Sep; 102(3):444-456. PubMed ID: 36509697
[TBL] [Abstract][Full Text] [Related]
5. Imidazoles and benzimidazoles as tubulin-modulators for anti-cancer therapy.
Torres FC; García-Rubiño ME; Lozano-López C; Kawano DF; Eifler-Lima VL; von Poser GL; Campos JM
Curr Med Chem; 2015; 22(11):1312-23. PubMed ID: 25620093
[TBL] [Abstract][Full Text] [Related]
6. Cyclostreptin derivatives specifically target cellular tubulin and further map the paclitaxel site.
Calvo E; Barasoain I; Matesanz R; Pera B; Camafeita E; Pineda O; Hamel E; Vanderwal CD; Andreu JM; López JA; Díaz JF
Biochemistry; 2012 Jan; 51(1):329-41. PubMed ID: 22148836
[TBL] [Abstract][Full Text] [Related]
7. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC
Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837
[TBL] [Abstract][Full Text] [Related]
8. βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.
Kanakkanthara A; Rowe MR; Field JJ; Northcote PT; Teesdale-Spittle PH; Miller JH
Cancer Lett; 2015 Sep; 365(2):251-60. PubMed ID: 26052091
[TBL] [Abstract][Full Text] [Related]
9. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
10. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.
Wilson L; Panda D; Jordan MA
Cell Struct Funct; 1999 Oct; 24(5):329-35. PubMed ID: 15216890
[TBL] [Abstract][Full Text] [Related]
11. Novel shikonin derivatives targeting tubulin as anticancer agents.
Guo J; Chen XF; Liu J; Lin HY; Han HW; Liu HC; Huang SC; Shahla BK; Kulek A; Qi JL; Wang XM; Ling LJ; Yang YH
Chem Biol Drug Des; 2014 Nov; 84(5):603-15. PubMed ID: 24797889
[TBL] [Abstract][Full Text] [Related]
12. Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid.
Yin S; Cabral F; Veeraraghavan S
Mol Cancer Ther; 2007 Oct; 6(10):2798-806. PubMed ID: 17938271
[TBL] [Abstract][Full Text] [Related]
13. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin.
Sharma A; Sáez-Calvo G; Olieric N; de Asís Balaguer F; Barasoain I; Lamberth C; Díaz JF; Steinmetz MO
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640209
[TBL] [Abstract][Full Text] [Related]
14. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics.
Waight AB; Bargsten K; Doronina S; Steinmetz MO; Sussman D; Prota AE
PLoS One; 2016; 11(8):e0160890. PubMed ID: 27518442
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent microtubule-destabilizing agents targeting for colchicine site by virtual screening, biological evaluation, and molecular dynamics simulation.
Zhang H; Luo QQ; Hu ML; Wang N; Qi HZ; Zhang HR; Ding L
Eur J Pharm Sci; 2023 Jan; 180():106340. PubMed ID: 36435355
[TBL] [Abstract][Full Text] [Related]
17. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.
Hari M; Wang Y; Veeraraghavan S; Cabral F
Mol Cancer Ther; 2003 Jul; 2(7):597-605. PubMed ID: 12883031
[TBL] [Abstract][Full Text] [Related]
18. Microtubule targeting agents: from biophysics to proteomics.
Calligaris D; Verdier-Pinard P; Devred F; Villard C; Braguer D; Lafitte D
Cell Mol Life Sci; 2010 Apr; 67(7):1089-104. PubMed ID: 20107862
[TBL] [Abstract][Full Text] [Related]
19. New tubulin targeting agents currently in clinical development.
Carlson RO
Expert Opin Investig Drugs; 2008 May; 17(5):707-22. PubMed ID: 18447597
[TBL] [Abstract][Full Text] [Related]
20. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine.
Rathinasamy K; Jindal B; Asthana J; Singh P; Balaji PV; Panda D
BMC Cancer; 2010 May; 10():213. PubMed ID: 20482847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
